Calling all Infinity Pharmaceuticals, Inc. (INFI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit!
Werte in diesem Artikel
NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI) and certain of its officers.
Class Definition:
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Infinity securities between January 5, 2023 and July 24, 2023, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/infi.
Case Details:
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Infinity overstated its prospects for a breast cancer treatment; (2) Infinity was overly optimistic about its breast cancer studies; (3) all the foregoing, once revealed, was likely to negatively impact Infinity's business, financial results, and reputation; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
What's Next?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: www.bgandg.com/infi, you may also contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Infinity you have until October 16, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | info@bgandg.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/calling-all-infinity-pharmaceuticals-inc-infi-investors-contact-bronstein-gewirtz--grossman-llc-to-actively-participate-in-the-class-action-lawsuit-301909527.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
Ausgewählte Hebelprodukte auf Infinity Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Infinity Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Infinity Pharmaceuticals Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Infinity Pharmaceuticals Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Infinity Pharmaceuticals nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 27.06.19 | Infinity Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
| 04.01.19 | Infinity Pharmaceuticals Buy | B. Riley FBR | |
| 15.06.16 | Infinity Pharmaceuticals Sector Perform | RBC Capital Markets | |
| 14.06.16 | Infinity Pharmaceuticals Mkt Perform | FBR Capital | |
| 02.03.16 | Infinity Pharmaceuticals Outperform | FBR Capital |
